{"id":830193,"date":"2025-03-26T16:08:01","date_gmt":"2025-03-26T20:08:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/journey-medical-corporation-reports-full-year-2024-financial-results-and-recent-corporate-highlights\/"},"modified":"2025-03-26T16:08:01","modified_gmt":"2025-03-26T20:08:01","slug":"journey-medical-corporation-reports-full-year-2024-financial-results-and-recent-corporate-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/journey-medical-corporation-reports-full-year-2024-financial-results-and-recent-corporate-highlights\/","title":{"rendered":"Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights"},"content":{"rendered":"
\n

\n FDA Approval of Emrosi\u2122 (<\/em>40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea<\/em><\/p>\n

\n Emrosi Initial Distribution Ongoing; First Prescriptions Filled<\/em>\n <\/p>\n

\n Total<\/em>
\n Revenues<\/em>
\n for the Full Year Ended December 31, 2024 <\/em>
\n were<\/em>
\n $56.1<\/em>
\n million<\/em>\n <\/p>\n

\n Met All Financial Guidance for 2024<\/em>\n <\/p>\n

\n Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology <\/em>\n <\/p>\n

\n Company to Hold Conference Call Today at 4:30 p.m. ET <\/em>\n <\/p>\n

SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (\u201cJourney Medical\u201d or \u201cthe Company\u201d, \u201cwe\u201d, or \u201cour\u201d), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (\u201cFDA\u201d) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2024.<\/p>\n

Claude Maraoui, Journey Medical\u2019s Co-Founder, President and Chief Executive Officer, said, \u201cWe delivered a solid performance in 2024, meeting all of our financial guidance ranges and received first cycle FDA approval for Emrosi\u2122 in November, ahead of the scheduled PDUFA date. Emrosi\u2019s superb Phase 3 clinical results demonstrated its best-in-class profile, and we expect it will become the standard of care and transform our business. Our cash position remains strong ahead of Emrosi\u2019s launch and our objective is to deliver enhanced revenue growth and become sustainably EBITDA positive. I am pleased to report that we have begun distribution of Emrosi, that first prescriptions have been dispensed and that we continue to execute ahead of schedule, with full promotion expected in April 2025.\u201d<\/p>\n

\n 2024 Financial Guidance:<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n Full Year 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n Full Year 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n ($’s in millions)<\/em>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n Financial Guidance<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n Actual Results<\/strong>
\n
\n
\n <\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u200b<\/td>\n\n \u200b<\/strong>\n <\/td>\n\n \u200b<\/strong>\n <\/td>\n\u00a0<\/td>\n\u200b<\/td>\n\n \u200b<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Product revenue, net<\/td>\n\u00a0<\/td>\n$<\/td>\n55 – 60<\/td>\n\u200b<\/td>\n\u00a0<\/td>\n$<\/td>\n55.1<\/td>\n\u00a0<\/td>\n<\/tr>\n
Selling general and administrative (“SG&A”) expense<\/td>\n\u00a0<\/td>\n$<\/td>\n39 – 42<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n40.2<\/td>\n\u00a0<\/td>\n<\/tr>\n
Research and development (“R&D”) expense<\/td>\n\u00a0<\/td>\n$<\/td>\n9 – 10<\/td>\n\u200b<\/td>\n\u00a0<\/td>\n$<\/td>\n9.9<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n 2024 Financial Results: <\/strong>\n <\/p>\n